A scheme called the International Horizon Scanning Initiative will allow ten European countries to work together on a database of medicines and reduce drug prices.
List view / Grid view
Drug Supply Chain
Filter the results
In this in-depth focus are articles exploring the global situation for drug packaging serialisation as well as an assessment of using drones to deliver medicines and how this impacts safety and quality.
The FDA has compiled a report which identifies the root causes of medicine shortages and suggests potential ways to alleviate scarcities.
Within this issue is an analysis of the impacts that low temperature can have on protein aggregation, a discussion on maintaining the safety and quality of medicines when delivered using drones and an exploration of chromatographic techniques used to identify impurities in radiopharmaceuticals. Other articles focus on regulatory non-compliance, excipients…
Loss of manufacturing capability as a result of regulatory non-compliance can have a devastating impact on biopharma or medical device manufacturers. In this article, Jenny Yu shares real-life examples from the industry and highlights the downstream effects of these business interruptions.
The DHSC and three companies have signed contracts worth £25 million to ensure that essential medicines can be supplied to the UK in 24 to 48 hours.
Four companies have agreed with the UK government to deliver medicines to the country after Brexit, signing contracts worth £86.6 million.
The Secretary of State for Health and Social Care is supporting the continuity of medical supplies if the UK is to leave the EU without a deal.
Researchers have found three factors that must be taken into account when compiling an essential medicines list for Canada.
The UK Competition and Markets Authority has alleged that Aspen paid two other pharmaceutical companies to ensure they were the only supplier of a drug to the NHS.
The government has announced new measures to prevent parallel exporting to ease the supply chain, in an effort to reduce medicine shortages.
The FDA and DEA have, for the first time, sent joint warning letters to four networks which were illegally selling opioid products.